Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on COBHAM PLC. We currently have 8 research reports from 3 professional analysts.
|20Mar17 14:39||RNS||Annual Financial Report|
|20Mar17 14:36||RNS||Annual Financial Report|
|02Mar17 07:00||RNS||Proposed Fully Underwritten Rights Issue|
|02Mar17 07:00||RNS||Final Results|
|27Feb17 14:05||RNS||Director Declaration|
|24Feb17 09:30||RNS||Holding(s) in Company|
|20Feb17 14:23||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
Have we (finally) reached the bottom?
02 Mar 17
Cobham released its FY results, a few weeks after its last profit warning which had already given almost all the negative news (i.e. some impairments and exceptional charges). Today the company announced what we were expecting, a £500m rights issue to strengthen the balance sheet. Finally, and as was also expected, the company will not distribute any dividend in 2017 considering the low cash flow generation, the really uncertain outlook for 2017 and the remaining issues it faces.
Sombre 2016 and lost faith in the future
16 Feb 17
Cobham released today an umpteenth profit warning two weeks before it releases its annual results. This time it not only concerns the operational issues, but also gives colour to the impact of the weak company performance on the asset-carrying value in the balance sheet. Moreover, the company looks clearly worried about 2017 and expects a worse year than the already tough one that has just ended.
10 Nov 16
History is likely to call 2016 Cobham’s annus horribilis. In 2015 the future looked bright, with the company delivering its first organic growth in 10 years. However, 2016 has seen three profit warnings and both the CEO and CFO resign. Two recent acquisitions, Axell Wireless and Aeroflex, have proved extremely challenging to integrate into Cobham, taking the wireless business from a 15% margin to significantly loss making. The company is in a hiatus as it awaits new management – CEO David Lockwood (Laird) and CFO David Mellors (QinetiQ) – so 2017 could be the start of a new era.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.
N+1 Singer - Augean - Double digit growth in ’16, good start to ‘17
21 Mar 17
Augean reported another year of double digit growth for 2016, with profits in line with our forecasts. Sales grew by 21% excluding landfill tax, while adjusted PBT grew by 18% to £7.1m before amortisation of acquired intangibles. DPS was increased by 54% to 1.0p, 25% ahead of our estimate. The business units made further strategic progress, with revenues from their top 20 customers increasing from 42% to 43% of the total, of which 88% was under contract or a framework agreement, increasing forward visibility. There has been an encouraging start to 2017 and management is confident of delivering another year of profits growth. The shares trade on undemanding single digit multiples, offering good value.
Scott deal puts spotlight back on corporate strategy and valuation
17 Mar 17
The acquisition of Scott Safety by 3M announced yesterday is not a huge surprise but it puts the spotlight back on (1) Avon’s corporate strategy as two strong competitors merge and (2) Avon’s break-up valuation given the rich multiple (12.9x EBITDA) being paid by 3M. Avon and other competitors, particularly MSA Safety, cannot ignore the fact that Scott, which is the leader in SCBA (self-contained breathing apparatus) market and 3M, which derives the bulk of sales from industrial hard hats and masks, would together have the most comprehensive portfolio of products in the PPE (Personal Protective Equipment) market. The good news for investors is that if we were to apply similar EBITDA multiple, then Avon’s Protection & Defence business alone would account for the entire market cap. In effect, at the current share price, investors are getting the Dairy business for free. Our sum-of-the parts model now values the shares at 1,279p, up 7% compared with 1,200p previously.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017